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Abstract 
Background: Treatment of patients affected by severe burns is challenging, especially due to the high risk of Pseu-
domonas infection. In the present work, we have generated a novel model of bioartificial human dermis substitute by 
tissue engineering to treat infected wounds using fibrin‑agarose biomaterials functionalized with nanostructured lipid 
carriers (NLCs) loaded with two anti‑Pseudomonas antibiotics: sodium colistimethate (SCM) and amikacin (AMK).
Results: Results show that the novel tissue‑like substitutes have strong antibacterial effect on Pseudomonas cultures, 
directly proportional to the NLC concentration. Free DNA quantification, WST‑1 and Caspase 7 immunohistochemi‑
cal assays in the functionalized dermis substitute demonstrated that neither cell viability nor cell proliferation were 
affected by functionalization in most study groups. Furthermore, immunohistochemistry for PCNA and KI67 and 
histochemistry for collagen and proteoglycans revealed that cells proliferated and were metabolically active in the 
functionalized tissue with no differences with controls. When functionalized tissues were biomechanically character‑
ized, we found that NLCs were able to improve some of the major biomechanical properties of these artificial tissues, 
although this strongly depended on the type and concentration of NLCs.
Conclusions: These results suggest that functionalization of fibrin‑agarose human dermal substitutes with antibiotic‑
loaded NLCs is able to improve the antibacterial and biomechanical properties of these substitutes with no detect‑
able side effects. This opens the door to future clinical use of functionalized tissues. 
Keywords: Tissue engineering, Functionalization, Dermal substitute, Severe burns, Human skin, Nanostructured lipid 
carriers, Colistimethate, Amikacin
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Background
Tissue engineering strategies attempt to generate biologi-
cally active tissue-like substitutes to restore and maintain 
the normal function of damaged tissues and organs [1]. 
Tissue engineering protocols combine the principles of 
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engineering and biological sciences to create artificial 
substitutes based on three main components: cells, bio-
compatible scaffolds and bioactive factors [1–4].
Among the different biomaterials that showed preclini-
cal and clinical usefulness for the generation of human 
tissue substitutes, fibrin-agarose hydrogels show excel-
lent biocompatibility and biomechanical properties and 
its porous fibrillar pattern allows diffusion and inter-
change of oxygen and nutrients [2, 3, 5, 6]. Fibrin-agarose 
was previously used to generate bioartificial substitutes 
of the human cornea [7], sclera [8], oral mucosa [9], pal-
ate [10], nerve [11, 12], cartilage [13] and skin [14, 15]. 
In fact, a bioartificial model of tissue-engineered human 
skin (UGRSKIN), consisting of a dermal skin substitute 
based on fibrin-agarose biomaterials and dermal fibro-
blasts and an overlying epithelial layer, has been success-
fully translated to the clinical setting [16]. The UGRSKIN 
model was approved by the National Medicines Agency 
in Spain (Agencia Española de Medicamentos y Produc-
tos Sanitarios—AEMPS) and is currently being used 
as an Advanced Therapy Medicinal Product (ATMP) in 
patients with severe skin burns [16]. Although prelimi-
nary clinical results of this model are very positive, fur-
ther research is needed in order to enhance the biological 
properties of these bioartificial tissues and improve their 
clinical efficiency.
In this regard, one of the main clinical challenges in 
patients affected by severe skin burns is preventing bac-
terial infection [17–19]. Specifically, Pseudomonas aer-
uginosa is one of the main pathogens that first colonizes 
burn wounds and can produce severe respiratory sys-
tem and systemic complications that can compromise 
patient’s life [17, 18, 20]. However, the treatment of these 
infections through conventional antibiotic therapies is 
often difficult due to the wide range of antimicrobial mul-
tidrug resistance of this pathogen and the low bioavail-
ability of certain antibiotics [21, 22].
As an alternative against multidrug-resistant bacteria, 
new drug delivery systems have emerged. Among them, 
nanostructured lipid carriers (NLCs) have gained atten-
tion as promising second-generation of lipid-based deliv-
ery systems, allowing efficient drug delivery to target 
tissues. In particular, NLCs are capable of exerting a local 
effect when topically administered on a wound, as dem-
onstrated by Vairo et  al. [23]. Moreover, antimicrobial 
activity can be increased when anti-Pseudomonas anti-
biotics are loaded in these nanoparticles by enhancing 
the interaction between the biofilm-bearing colony and 
the antibiotics. In addition, nanoencapsulation provides 
sustained controlled release able to reduce drug dose 
and thus, decrease drug toxicity and improve the safety 
profile of well-known antibiotics such as sodium colis-
timethate (SCM) and amikacin (AMK) [24–27].
In the present work, we have functionalized the previ-
ously available fibrin-agarose biomaterial with antibiotic-
loaded NLCs in order to provide antimicrobial properties 
to the biomaterial. Then, the resulting functionalized 
biomaterial was used to generate a functionalized model 
of the human skin dermis (FSS) produced by tissue engi-
neering. This novel dermal skin substitute could contrib-
ute to improve the clinical performance and usefulness of 
currently-available fibrin-agarose skin models (SS).
Results
Antibiotic‑loaded nanoparticle characterization
Nanoparticle size was 132.9 ± 3.4, 123.12 ± 4.11 and 
116.8 ± 9.2  nm, for AMK-NLCs, SCM-NLCs and CTR-
NLCs, respectively. Dispersion analysis resulted in a satis-
factory particle homogeneity for all samples (SPAN < 0.8). 
Besides, the used preparation method led to a final anti-
biotic loading of 0.06 mg drug/mg and an encapsulation 
efficiency of 93.24 ± 2.21 and 77.25 ± 7.04%, for AMK-
NLCs and SCM-NLCs, respectively.
Biocompatibility analysis
Quantification of DNA released to the culture medium 
as a result of cell damage revealed that most experimen-
tal conditions were associated to very low levels of DNA 
(Table  1). After 24  h, we found that the lowest concen-
trations of each type of NLCs (10 and 100  µg/ml) were 
not associated to significant levels of released DNA (dif-
ferences with positive controls were non-significant, 
whereas differences with negative controls were sta-
tistically significant). However, FSS-AMK1000, FSS-
SCM300 and FSS-SCM1000 showed low amounts of 
DNA released to the medium, although differences with 
positive controls were statistically significant. At 48 h, we 
found that the highest concentrations of the three types 
of NLCs (1000  µg/ml), along with FSS-SCM10 showed 
low amounts of released DNA, showing statistically sig-
nificant differences as compared to positive controls. In 
all cases, the amount of DNA was significantly lower than 
negative controls.
For the WST-1 metabolic assay (Table  1), results dif-
fered for the two follow-up times evaluated. After 24 h, 
the metabolic function was partially diminished (less 
than 15%) in cells in contact with the lowest concen-
trations (10 and 100 µg/ml) of the three types of NLCs, 
and for FSS-AMK300, FSS-CTR300 and FSS-CTR1000, 
as compared to positive controls, with all cases showing 
significant differences with negative controls. Following 
48  h, FSS showed non-significant differences with posi-
tive controls, but were significantly lower than negative 
controls.
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Histological analysis
Histological analysis of the different bioengineered 
human dermal skin substitutes generated in the present 
work revealed that human skin fibroblasts displayed 
a normal morphology and structure in all experimen-
tal conditions (Fig.  1). At 24  h, cells showed the typical 
elongated or spindle-shape morphology of human fibro-
blasts, with no differences between FSS and control non-
functionalized SS, as occurred after 48  h. In SS and all 
FSS groups, the fibrin-agarose biomaterial consisted of 
a fibrillar mesh with abundant porous spaces among the 
randomly distributed fibrils. Cells were able to spread 
within the fibrin-agarose biomaterial mesh and cell pro-
longations (pseudopods or filopodia) were emitted in all 
spatial directions. No signs of cell death were found in 
any of the samples. These findings are in agreement with 
the immunohistochemical analysis of caspase 7 showing 
negative expression of this apoptosis marker in control 
non-functionalized skin substitutes and in all FSS groups 
at 24 and 48 h (Fig. 1).
On the other hand, cell proliferation was analyzed in 
control and FSS groups to determine the effect of func-
tionalization on this parameter. In this regard, immuno-
histochemical analysis of the cell proliferation markers 
PCNA and KI67 demonstrated that cells were able to 
proliferate inside all types of tissue substitutes, especially 
after 48  h. In fact, we found PCNA-positive cells in all 
study groups at 24 and 48 h, and KI67-positive cells in all 
groups at 48 h (Fig. 2).
To determine the effect of functionalization on the bio-
synthetic activity of the cells immersed in the FSS, syn-
thesis of collagen fibers and proteoglycans was analyzed 
by picrosirius and alcian blue histochemistry, respec-
tively. Results showed that the amount of these ECM 
proteins was very low in controls and FSS, with no dif-
ferences among groups (Fig.  3). First, collagen fibers 
were mostly absent in all groups, with very few signals 
restricted to the intracellular space of the stromal cells. 
However, proteoglycans were comparatively more abun-
dant than collagen fibers, although their expression was 
very low at 24 and 48 h and was also restricted to the cell 
cytoplasm. No differences were found between FSS and 
control samples.
Antibacterial efficiency of FSS
To assess the antibacterial effect of functionalized tissues, 
FSS containing the different types of NLCs were cul-
tured on surfaces seeded with live P. aeruginosa. Results 
showed that the inhibition area (Fig. 4) was highly related 
to the antibiotic dose, and a statistically significant cor-
relation between concentration and inhibition area was 
found for FSS-AMK and FSS-SCM samples (p = 0.00013 
and 0.00280, respectively), but not for FSS-CTR (p > 0.05), 
as no antibiotic was loaded in the NLCs embedded 
within these substitutes. When the type of antibiotic-
loaded NLCs was considered, the inhibition area was 
significantly related to the antibacterial efficiency of FSS 
(p < 0.00001 for the Kruskal–Wallis test), with significant 
differences between FSS-AMK and FSS-CTR (p < 0.00001 
for the Mann–Whitney test) and between FSS-SCM and 
FSS-CTR (p < 0.00001 for the same test), with no differ-
ences between FSS-AMK and FSS-SCM (p > 0.05). For 
specific concentrations, the highest inhibitory efficiency 
corresponded to FSS-AMK300 and FSS-AMK1000, with 
no significant differences between these two concentra-
tions. Interestingly, the efficiency was higher for each 
concentration of FSS-AMK as compared to the same 
concentration of FSS-SCM, except for 10 µg/ml (Fig. 4).
Biomechanical properties of FSS
Analysis of the biomechanical properties of the different 
human dermal skin substitutes generated in this work 
showed that the type and concentration of NLCs could 
influence these properties.
In the first place, the Young modulus of controls and 
FSS was analyzed (Fig.  5a). Results showed that con-
trol non-functionalized SS had a Young modulus of 
0.1223 ± 0.0398  MPa. When bioartificial tissues were 
functionalized with 10 µg/ml of AMK-NLCs and 10, 100 
and 300  µg/ml of SCM-NLCs, a significant increase in 
this parameter was found as compared with SS. In con-
trast, FSS-SCM1000 and FSS-CTR300 samples showed 
a significant decrease in this parameter. Non-signifi-
cant differences with SS were found for the rest of FSS. 
Interestingly, a significant correlation between the NLC 
concentration and the Young modulus was found for 
FSS-AMK samples (p < 0.001), but not for FSS-SCM or 
FSS-CTR.
In the second place, to determine the deformation 
capability of each sample to a traction load before rup-
ture, the strain at fracture break and the traction defor-
mation parameters was evaluated (Fig.  5b, c). In this 
regard, the strain at fracture break of non-functionalized 
SS was 31.12 ± 6.99 mm, corresponding to 311.1 ± 69.9% 
of traction deformation. When the dermal substitutes 
were functionalized, a significant increase of both param-
eters was shown in FSS-SCM1000 and FSS-CTR300, and 
a significant decrease in FSS-SCM10 and FSS-SCM300. 
For FSS-AMK, a non-significant increasing trend up to 
300  µg/ml was found. Correlation with the concentra-
tion of NLCs was statistically significant for FSS-CTR 
(p = 0.0306), but not for FSS-AMK or FSS-SCM.
Finally, the stress at fracture break and the break 
load parameters of controls and FSS was assessed 
to determine the force that each sample was able 
to bear before fracturing (Fig.  5d, e). SS showed 
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0.4738 ± 0.0999  MPa for the stress at fracture break 
and 0.2369 ± 0.05  N for the break load. Functional-
ized dermal substitutes showed a significant increase 
of both parameters in FSS-AMK10 and FSS-AMK100, 
and a significant decrease in FSS-AMK1000 and FSS-
CTR1000. A significant correlation was found between 
the concentration of NLCs and the stress at fracture 
break or the break load for the three types of NLCs 
(AMK-NLCs, p = 0.0055; SCM-NLCs, p = 0.0268; 
CTR-NLCs, p = 0.0024).
Discussion
As the largest organ in the body, the skin is the primary 
protective barrier between an individual and the sur-
rounding environment. Among the main conditions 
severely affecting the human skin, large burns are life-
threatening situations. One of the therapeutic tools 
showing promising results in these patients is the UGR-
SKIN model [16], but further research is still in need to 
improve the efficiency of this ATMP.
Burn injuries typically destroy the skin integrity, and 
avascularity, protein rich environment and generalized 
immune suppression make burn wounds particularly 
susceptible to infections [17–20]. One of the most com-
mon bacterial species affecting burn patients is P. aer-
uginosa [17–20], and its presence may significantly 
worsen prognosis and survival rate. To overcome these 
limitations, different innovative approaches have been 
described, such as biomaterial functionalization with gra-
phene oxide [32] or montmorillonite [33]. However, the 
inability to control severe burn-related infections is still 
challenging.
In the present study, we generated an improved dermal 
skin substitute by combining the regenerative properties 
of the UGRSKIN model with antibiotic-loaded NLCs. 
These nanoparticles already demonstrated to be an effec-
tive drug delivery system suitable for the treatment of P. 
aeruginosa infections [24], with no associated in vivo side 
effects [26, 27].
Our results first demonstrated that functionalization 
with NLCs was very effective, and FSS showed strong 
antibacterial effectiveness on P. aeruginosa cultures. In 
the first place, we found that the antibacterial activity of 
the FSS was dose-dependent with a strong correlation 
between the concentration of antibiotics and the bacte-
rial inhibition area. This finding was unsurprising, since 
dose-dependent antibacterial effect is one of the main 
Fig. 1 Hematoxylin–eosin histological analysis and caspase 7 immunohistochemistry of dermal fibroblast cells in the different groups. SS: 
non‑functionalized human dermal skin substitutes, FSS: functionalized human dermal skin substitutes containing different types of NLCs (AMK, SCM 
or CTR) at different concentrations (10, 100, 300 or 1000 µg/ml). Scale bar: 10 µm
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characteristics of most known antibiotics [34], although 
this is the first time that this phenomenon is demon-
strated for nanoencapsulated antibiotics combined 
with fibrin-agarose hydrogels. As previously demon-
strated, the use of antibiotic-loaded NLCs is associated 
to a significant reduction of the antibiotic doses needed 
for an efficient ex  vivo and in  vivo effect, and twofold 
reduction in the inhibition area was obtained as com-
pared to free antibiotics [27].
In the second place, our results showed that both 
types of antibiotics (AMK and SCM) were very effec-
tive against P. aeruginosa as compared to controls, and 
a global comparison between both antibiotics revealed 
non-significant differences. In general, these results sug-
gest that both, AMK and SCM loaded into NLCs, could 
be promising tools that may provide antimicrobial prop-
erties to functionalized dermal substitutes in order to 
treat or prevent bacterial wound infections. However, a 
detailed comparison of specific concentrations showed 
that AMK was more efficient than SCM for the highest 
concentrations. Moreover, considering that P. aeruginosa 
is one of the bacteria responsible for antimicrobial resist-
ance (AMR), a major global threat facing public health 
[35], the fact that our improved dermal substitute can be 
functionalized with AMK and SCM, two of the few anti-
biotics effective against gram-negative resistant bacteria, 
provides added value to this ATMP.
In general, these results confirm the ex vivo usefulness 
of the functionalized models of human dermis described 
in the present work, and suggest that both antibiotics 
could be effective for preventing P. aeruginosa infections 
of the wound bed. The fact that both antibiotics were 
efficient opens the door to the possibility of using one of 
them as a first-line treatment for severe skin burns, and 
reserving the other antibiotic as a second-line option, 
although a combination of both in a single FSS could 
also be an option. Future studies should be carried out 
to determine the most adequate composition of FSS for 
clinical use.
On the other hand, one of the most important require-
ments for therapeutic use of biomaterials in tissue engi-
neering is biosafety [36]. In this regard, evaluation of the 
side effects of functionalization is necessary before FSS 
can be clinically used. For this reason, we analyzed several 
parameters directly related to biosafety in FSS, including 
biocompatibility, cell viability, proliferation and ex  vivo 
function. Our results first showed that most cells in the 
FSS were alive, with no structural membrane damage 
Fig. 2 Immunohistochemical analysis of dermal fibroblast cells in the different groups for the cell proliferation markers PCNA and KI67. SS: 
non‑functionalized human dermal skin substitutes, FSS: functionalized human dermal skin substitutes containing different types of NLC (AMK, SCM 
or CTR) at different concentrations (10, 100, 300 or 1000 µg/ml). Scale bar: 10 µm
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demonstrated by quantification of free DNA released to 
the culture medium and no morphological alterations as 
determined by HE staining. Cell viability was higher than 
90% in all conditions, confirming the high biocompatibil-
ity of these nanoparticles [27]. Although cell proliferation 
and metabolic function, as determined by WST-1, was 
Fig. 3 Histochemical analysis of dermal fibroblast cells in the different groups using picrosirius red (for collagen identification) and alcian blue (for 
proteoglycans). SS: non‑functionalized human dermal skin substitutes, FSS: functionalized human dermal skin substitutes containing different types 
of NLCs (AMK, SCM or CTR) at different concentrations (10, 100, 300 or 1000 µg/ml). Scale bar: 10 µm
Fig. 4 P. aeruginosa inhibition area generated by each type of FSS. Representative images are shown in the left panel, and quantified results are 
shown at the right. For quantification, results are shown as average percentage values with error bars corresponding to standard deviations
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partially reduced at 24 h, cells were able to recover their 
initial condition after 48  h, which is in agreement with 
our immunohistochemical results for KI67. Previous 
results demonstrated that cells immersed in hydrogels for 
tissue engineering use could need some time to adapt to 
the new culture conditions and may require some days to 
fully recover the initial cell number and function [37, 38]. 
All these results confirm that FSS fulfill the biocompat-
ibility requirements of bioartificial tissues for future clini-
cal, as previously described [27].
These findings are in agreement with the immunohisto-
chemical analyses of the dermal skin substitutes showing 
negative reaction for caspase 7, a marker of apoptotic cell 
death, which reinforces the non-toxic effects of the NLCs 
used in this work. Similarly, we found a positive immuno-
histochemical reaction for the cell proliferation markers 
KI67 and PCNA, confirming the functional status of the 
cells in all FSS groups. The different behavior found for 
PCNA and KI67 could be explained by the longer half-
life of the PCNA protein (at least 20  h), which implies 
Fig. 5 Biomechanical properties of control (SS) and functionalized samples (FSS) generated with different types and concentrations of NLCs. a: 
Young modulus, b: strain at fracture break, c: traction deformation, d: stress at fracture break, e: break load. Results are shown as mean values, and 
error bars correspond to standard deviations
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that nuclei could continue to express PCNA even after 
completing the cell cycle [39], whereas KI67 is known to 
be more sensitive and specific [40].
After demonstrating that the nanoparticles used in the 
present work were safe for the cells immersed in the der-
mal substitute, we analyzed the influence of these NLCs 
on the biosynthetic capability of the FSS cells. Results 
showed that the synthesis of collagen and proteoglycans, 
the most important extracellular matrix components 
synthetized by the dermal substitute of a bioartificial 
skin [15], were actively synthetized by the FSS cells, with 
no differences with controls. Although longer follow-up 
studies should be carried out, these preliminary results 
confirm that functionalization of the human dermal skin 
substitute did not affect negatively the human dermal 
cells. Fibroblasts remained viable, morphologically nor-
mal and biosynthetically functional as they were in non-
functionalized human dermal skin substitutes.
In addition, bioengineered tissues should resemble the 
native tissues not only at histological level, but also from 
a biomechanical standpoint. For this reason, in the pre-
sent work we performed a biomechanical characteriza-
tion of the FSS in order to determine if functionalization 
may have modified the main properties of these bioar-
tificial tissues, and to assess if the incorporation of the 
different types of NLCs could have changed the three-
dimensional structure of the biomaterial and, therefore, 
its biomechanical properties. A proper biomechanical 
characterization of the novel FSS would contribute to 
future clinical translation, since a comprehensive charac-
terization of novel tissue substitutes is a requirement of 
all National Medicines Agencies before clinical use [3, 36, 
41, 42]. Thus, once effectivity and safety of the function-
alized human dermal skin substitutes were proven, we 
decided to test the biomechanical properties of the FSS. 
In general, our results showed that both the type and 
concentration of NLCs could influence the biomechani-
cal properties of the human dermal skin substitutes.
Interestingly, we found that functionalization was 
able to modify the Young modulus of the FSS in a dose 
and type-dependent manner. In this regard, we found 
a statistically significant increase of this parameter 
in FSS containing the lowest concentrations of AMK 
and SCM nanoparticles as compared to the SS group, 
whereas the highest concentrations showed the oppo-
site effect. Strikingly, the use of CTR-NLCs showed a 
different behavior. As the Young modulus is directly 
linked to the biomaterial stiffness [6], these results sug-
gest that antibiotic-loaded NLCs could be used not only 
for tissue functionalization, but also to improve the bio-
mechanical properties and stiffness of human tissue sub-
stitutes. Related to the Young modulus, we analyzed the 
stress at fracture break and break load of each type of 
bioengineered human skin. Both parameters are associ-
ated to the maximum stress force that the bioartificial tis-
sues can resist before irreversible damage [6]. As for the 
Young modulus, we found that functionalization with the 
lowest concentrations of nanoparticles, especially in the 
case of AMK, were able to improve the stiffness of the 
FSS, although a high concentration of particles resulted 
in the opposite effect.
Other critical biomechanical parameters of bioengi-
neered human tissues are the strain at fracture break and 
the traction deformation. Both parameters are related to 
the deformation that the bioartificial tissue can sustain 
before irreversible damage, and are strictly dependent on 
the tissue elasticity [6]. Remarkably, our results showed 
that these parameters were also dependent on the type 
and concentration of NLCs. Whereas low concentra-
tions of nanoparticles were associated to a loss of elas-
ticity, we found a significant increase of both parameters 
for the highest concentration of SCM-NLCs and in FSS-
CTR300, suggesting that the plastic deformation capabil-
ity of FSS can be modified upon functionalization.
Altogether, our biomechanical results show that 
functionalization of the dermal skin substitute can sig-
nificantly tune the biomechanical behavior of this bioar-
tificial tissue. In this line, not only the concentration, but 
also the type of encapsulated antibiotic, are associated 
to these biomechanical changes. This new generation 
of functionalized dermal skin substitutes could improve 
the biomechanical properties of the current UGRSKIN 
model by combining an optimum type and concentration 
of antibiotic-loaded nanoparticles.
The reasons why functionalization is able to increase 
or decrease the biomechanical properties of FSS requires 
further research. However, we may hypothesize that 
NLCs could associate to fibrin-agarose monomers during 
polymerization of the hydrogel and increase the biome-
chanical stability of the 3D fiber mesh, thus contributing 
to hold the incoming forces with higher efficiency. In fact, 
we previously found that different types of nanoparticles 
can be adsorbed on the fibrin fibers and increase the 
attraction between adjacent fibers, resulting in a signifi-
cant improvement of the biomechanical properties of the 
hydrogel [43]. On the opposite, it is likely that an excess 
of particles may interfere the fibrin-agarose polym-
erization process and alter the mesh polymerization. 
Regarding differences among the types of nanoparticles, 
previous reports showed that AMK and SCM have dif-
ferent hydrophobicity [27]. While AMK has lower water 
solubility and a higher affinity for the lipid phase, SCM 
typically has higher encapsulation efficacy and slower 
drug released profile. If this factor may influence link-
age of NLCs to the fibrin-agarose fibers should be deter-
mined in future studies.
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Conclusions
In conclusion, this ex  vivo study demonstrated that 
fibrin-agarose human dermis substitutes can be function-
alized with antibiotic-loaded NLCs, and that FSS show 
improved bioactive antibacterial properties as compared 
to controls, with no side effects for the cells embedded 
in the bioartificial tissue. Furthermore, functionalization 
was able to improve some of the main biomechanical 
parameters of FSS. Although future studies are in need to 
demonstrate the real effect of FSS in vivo, these prelimi-
nary promising results support the future clinical use of 
the novel functionalized dermal skin model.
Materials and methods
Antibiotic‑loaded nanoparticle preparation
AMK- or SCM-loaded NLCs (AMK-NLCs or SCM-
NLCs) and empty nanoparticles used as controls (CTR-
NLCs), were prepared by the hot melt homogenization 
technique following a modified protocol reported by Pas-
tor et al. [26], in which the sonication time was increased 
up to 30 s. Briefly,  Precirol® ATO 5 (Gattefossé, Madrid, 
Spain) and Miglyol 182 N/F (Gattefossé, Madrid, Spain) 
were melted with the antibiotic (AMK or SCM) to 
achieve the oily phase (10:1:1). In the case of empty nano-
particles, no antibiotic was used. Meanwhile, the aque-
ous phase was prepared dissolving  Tween® 80 (Panreac 
Química, Barcelona, Spain) at 1.3% (w/v) and Poloxamer 
188 (BASF, Ludwigshafen, Germany) at 0.6% (w/v) and 
then the solution was tempered above the melting tem-
perature of the solid lipid. Both phases were mixed and 
emulsified under sonication for 30 s at 50 W. The result-
ing emulsion was then gradually cooled down and kept 
at room temperature for 1  h under gentle stirring. Tre-
halose was added as cryo-preserving agent prior to the 
freeze-drying step in a final concentration of 15% (w/w) 
of the weighed lipid. Nanoparticles presented both, 
encapsulated and non-encapsulated antibiotics (on the 
nanoparticle surface), as no washing step was included 
during nanoparticle preparation.
Antibiotic‑loaded nanoparticle characterization
Nanoparticles were characterized in size and dispersion 
(SPAN) by means of Nanosight NS300 Zetasizer Nano 
ZS (Malvern Panalytical Ltd, Spain) based on nanoparti-
cle tracking analysis (NTA).
Drug loading was calculated by means of the following 
formula:
Besides, encapsulation efficiency was estimated indi-
rectly by quantifying the amount of antibiotic present in 
the supernatant as already described by Vairo et al. [27]. 
In short, 5 mL of the cooled suspension were centrifuged 
in an  Amicon® centrifugal filtration unit (100 kDa molec-
ular weight cut off, Millipore) for 15  min at 2500  rpm 
to analyze the amount of nonencapsulated drug. SCM 
amount was determined by using the Micro BCA™ Pro-
tein Assay Kit (Thermo Fisher Scientific, Spain) follow-
ing purchaser instructions. AMK was determined by the 
ultraviolet–visible (UV–vis) spectrophotometric tech-
nique for fluorescamine derivatization. Once quantified, 
encapsulation efficiency was measured according to the 
following formula:
Samples were analyzed in triplicates to obtain an accu-
rate mean, except for the drug loading.
Generation of non‑functionalized human dermal skin 
substitutes (SS) by tissue engineering
Primary cell cultures of dermal fibroblast cells were 
obtained from skin biopsies taken from healthy donors. 
Biopsies were carefully rinsed in phosphate-buffered 
saline and enzymatically digested in a 2 mg/ml Clostrid-
ium histolyticum collagenase I (Gibco–Thermo Fisher 
Scientific, Waltham, MA) solution at 37  °C for 6  h to 
obtain primary cell cultures of skin fibroblasts following 
previously described protocols [14, 15]. Isolated human 
dermal fibroblasts were then cultured in Dulbecco’s mod-
ified Eagle’s medium -DMEM- (Merck Life Science, St. 
Louis, MO) supplemented with 10% fetal bovine serum 
(Merck Life Science) and 1% antibiotics/antimycotics 
(100  U/mL penicillin G, 100  mg/ mL streptomycin and 
0.25 mg/mL amphotericin B; Merck Life Science) under 
standard cell culture conditions.
Bioengineered human dermal skin substitutes (SS) 
were generated using fibrin-agarose biomaterials as pre-
viously described [7, 9, 11, 14, 15, 28]. In brief, the follow-
ing components were mixed per each ml of dermal skin 
substitute: 760  µl of human plasma -as a fibrin source-, 
75  μl of DMEM containing 140,000 cultured human 
fibroblasts, 15  µl of tranexamic acid -as antifibrinolytic 
agent- (Amchafibrin, Fides-Ecofarma, Valencia, Spain), 
50  μl of a 2% solution of type VII agarose (Merck Life 
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(Merck Life Science) -to promote fibrin polymerization-. 
The mixture was aliquoted in culture plates and allowed 
to jellify for 24  h in a 37 ºC cell incubator. Then, each 
type of bioartificial tissue [SS and functionalized human 
dermal skin substitutes (FSS)] was subjected to plastic 
compression nanostructuration techniques as previously 
described [6, 11, 14].
Generation of functionalized human dermal skin 
substitutes (FSS) by tissue engineering
FSS were generated as described for SS, but a specific 
amount of each type of nanoparticle (final concentration 
of 10, 100, 300 and 1000 µg/ml) was incorporated to the 
hydrogel mixture right before inducing jellification of the 
solution by adding  CaCl2 in order to generate the follow-
ing types of FSS:
– FSS functionalized with AMK-NLCs at a final con-
centration of 10, 100, 300 and 1000  µg/ml (FSS-
AMK10, FSS-AMK100, FSS-AMK300 and FSS-
AMK1000, respectively).
– FSS functionalized with SCM-NLCs at a final con-
centration of 10, 100, 300 and 1000  µg/ml (FSS-
SCM10, FSS-SCM100, FSS-SCM300 and FSS-
SCM1000, respectively).
– FSS functionalized with CTR-NLCs at a final concen-
tration of 10, 100, 300 and 1000 µg/ml (FSS-CTR10, 
FSS-CTR100, FSS-CTR300 and FSS-CTR1000, 
respectively).
FSS were aliquoted and incubated at 37 ºC as per-
formed for SS, and nanostructuration was then applied.
Ex vivo analysis of biocompatibility of FSS
To determine the ex vivo biocompatibility of the bioen-
gineered dermal skin substitutes, SS and FSS were kept 
under standard culture conditions for 24  h and 48  h. 
After each time point, cell death was assessed by quan-
tifying free DNA released from ruptured cells to the 
culture medium using a NanoDrop 2000 UV–Vis Spec-
trophotometer (Thermo Fisher Scientific) as previously 
described [29]. In addition, cell function was analyzed by 
quantifying the mitochondrial dehydrogenase activity in 
live cells using the cell proliferation and viability reagent 
WST-1 (Roche Diagnostics, Mannheim, Germany) [29]. 
In both cases, live cells grown in basal medium were used 
as positive controls (CTR +), whilst cells incubated in 
1% triton X-100 were used as negative controls (CTR–). 
Results obtained in the experimental groups were nor-
malized to controls.
Histological analysis
To evaluate the effects of NLC functionalization on the 
dermal fibroblasts included in the dermal substitutes, 
cells were histologically evaluated after 24 and 48  h. SS 
and FSS were fixed in formalin, dehydrated and embed-
ded in paraffin by following standard histology proto-
cols. All samples were included in a tissue array and 
5 µm-sections were obtained with a microtome. Sections 
were dewaxed, rehydrated and stained with hematoxylin 
and eosin (HE) to study cell morphology and structure. 
To assess cell function, viability and proliferation, histo-
chemical and immunohistochemical analyses were car-
ried out using standard methods and techniques.
For immunohistochemistry, dewaxed tissue sections 
were incubated with specific primary antibodies anti-
caspase 7-for apoptotic cell death- (Abcam, ab69540; 
dilution 1:100), PCNA (Master Diagnostica, Granada, 
Spain; MAD-000903QD) and KI67 (Master Diagnos-
tica, Granada, Spain; MAD-000310QD) -both, for cell 
proliferation-. Then, samples were washed and incu-
bated in secondary anti-mouse or anti-rabbit antibodies 
(Vector Laboratories, MP-7402-0 or MP-7401-50), and 
the immunohistochemical signal was revealed using a 
diaminobenzidine (DAB) development kit (Vector Lab-
oratories). Samples were then briefly contrasted with 
Harris hematoxylin and mounted using glass coverslips. 
To identify the synthesis of fibrillar and non-fibrillar 
components of the dermis extracellular matrix by cells 
immersed in the different dermis substitutes, histo-
chemical methods for collagen fibers (picrosirius red) 
and proteoglycans (alcian blue) were used as previously 
described [30, 31].
Analysis of the anti‑microbial activity of FSS
Antimicrobial activity of FSS was determined by cultur-
ing each type of dermal substitute on a bacterial biofilm 
consisting of Pseudomonas aeruginosa. First, commer-
cially-available P. aeruginosa strains were purchased from 
Merck Life Science (NCTC 10,662  Lenticule® discs). 
Strains were precultured in Luria–Bertani (LB) broth at 
37ºC until turbidity bacterial suspension was achieved. 
100  µl of this bacterial suspension was then inoculated 
on LB-agar plates and allowed to dry. Then, each human 
dermal skin substitute (SS and FSS at increasing concen-
trations) was placed on top of the bacterial LB-agar sur-
face and cultured for 24 h in a cell incubator at 37 ºC. The 
inhibitory activity of each experimental group was then 
calculated by measuring the area of bacterial growth 
inhibition with the ImageJ software. Samples were ana-
lyzed in triplicates.
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Biomechanical characterization of dermal skin substitutes
To determine the effect of NLC functionalization on the 
biomechanical properties of each dermal skin substi-
tutes, SS and FSS were subjected to tensile tests using an 
electromechanical material testing instrument (Instron, 
Model 3345-K3327) as previously described [3, 6, 11]. 
In brief, dermal skin substitutes were sectioned to a rec-
tangular shape and oriented with their length along the 
direction of the tension. Each experimental group was 
clamped at each end of the instrument device, leaving 
a constant distance of 1 cm between the clamps and all 
tests were run at a constant strain rate of 5 mm/min at 
room temperature. Young modulus was calculated as 
the tangent modulus of the initial, linear portion of the 
stress–strain curve of each experimental run, while the 
stress at fracture break (σ break) and the strain at frac-
ture break (ε break) values were determined by selecting 
the point of the stress–strain curve where the fracture 
occurred. Traction deformation and break load were 
automatically calculated by the instrument. A 50-N 
Instron load cell was used to obtain the data for the 
stress–strain curves. Calculation of the average value and 
standard deviation (SD) of the results for each experi-
mental run was operated automatically, using the Instron 
Blue Hill 2 Material Testing software.
Statistical analysis
Non-parametric statistical tests were used for all compar-
isons because none of the study variables were normally 
distributed. To compare several groups of samples within 
the same variable, we used the Kruskal–Wallis test. Then, 
post-hoc comparisons between two specific groups of 
samples were carried out using Mann–Whitney tests. To 
determine the correlation between two different distribu-
tions, we used the Kendal tau correlation test. All statisti-
cal comparisons were performed using the RealStatistics 
software. For all tests, a p value < 0.05 was considered sta-
tistically significant for the double-tailed tests.
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